OncoMatch/Clinical Trials/NCT05803018
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies
Is NCT05803018 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies BL-B01D1 for gynecological malignant tumor.
Treatment: BL-B01D1 — A phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of BL-B01D1 for injection in patients with multiple solid tumors, including recurrent or metastatic gynecological malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment
failed standard treatment, intolerance to standard treatment, or no current standard treatment available
Cannot have received: chemotherapy
Received chemotherapy...within 4 weeks or 5 half-lives prior to the first dose (6 weeks for mitomycin and nitrosoureas; oral fluorouracil drugs, etc.)
Cannot have received: biological therapy
Received...biological therapy...within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: immunotherapy
Received...immunotherapy...within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: other antitumor treatments
Received...other antitumor treatments within 4 weeks or 5 half-lives prior to the first dose
Cannot have received: anthracycline
Cumulative anthracycline dose >360 mg/m² in prior (neo)adjuvant anthracycline therapy
Lab requirements
Blood counts
Toxicity from prior anti-tumor therapy has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0; Organ function levels must meet the requirements without transfusion, albumin, colony-stimulating factors, any cell growth factors, and/or platelet-raising drugs within 14 days before the first dose of the study drug; Coagulation function: INR ≤1.5, and APTT ≤1.5 × ULN; Urine protein ≤2+ or ≤1000 mg/24h
Kidney function
Liver function
Cardiac function
No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%
No severe cardiac dysfunction, with left ventricular ejection fraction (LVEF) ≥50%; Organ function levels must meet the requirements...; Coagulation function: INR ≤1.5, and APTT ≤1.5 × ULN; Urine protein ≤2+ or ≤1000 mg/24h
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify